Author/Authors :
Muٌoz، نويسنده , , Raquel D. Arias، نويسنده , , Yolanda and Ferreras، نويسنده , , José M. and Rojo، نويسنده , , Marيa A. and Gayoso، نويسنده , , Manuel J. and Nocito، نويسنده , , Mercedes and Benitez، نويسنده , , Jorge H. Jimenez، نويسنده , , Pilar and Bernabéu، نويسنده , , Carmelo and Girbés، نويسنده , , Tomas، نويسنده ,
Abstract :
Targeting tumour neovasculature using antibodies to the endothelial receptor CD105 (endoglin), is a potentially useful approach for anti-tumour therapy. We report on the preparation and the cytotoxicity of a novel immunotoxin consisting in the non-toxic type 2 ribosome-inactivating protein (RIP) nigrin b linked to the monoclonal anti-human CD105 (hCD105) antibody 44G4. The immunotoxin kills specifically mouse fibroblasts expressing the biomarker CD105 (L929-hCD105+ cells) with an IC50 value of 6 × 10−10 M while nigrin b does it at 2.4 × 10−7 M. Immunofluorescence analysis indicated that the immunotoxin accumulates in a perinuclear region. In contrast, 44G4 showed a specific localization on the cell surface.
Keywords :
Nigrin b , Endoglin , Anti-endoglin antibody , Anti-tumour therapy , Transfectant hCD105 cells
